Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

The Pennsylvania Act 1 of 2023 eligibility criteria for supplemental screenings based on breast density and lifetime risk of breast cancer disproportionately disqualify Black women from supplemental screenings despite their high risk of aggressive cancer and persistent history of false-negative mammograms.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Early-onset breast cancer was associated with hormone therapy usage in younger women in a recent study.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post menopause, a recent study found.